This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2017
  • /
  • 07
  • /
  • Sunovion divests US rights to Alvesco (ciclesonide...
Drug news

Sunovion divests US rights to Alvesco (ciclesonide), Omnaris (ciclesonide nasal spray) and Zetonna (ciclesonide nasal aerosol)to Covis.N.L

Read time: 1 mins
Last updated:17th Jul 2017
Published:17th Jul 2017
Source: Pharmawand

Sunovion has announced that it has entered into a definitive agreement to divest its US marketing rights to Sunovion's ciclesonide products, Alvesco (ciclesonide aerosol) for treatment of asthma , Omnaris (ciclesonide nasal spray) and Zetonna (ciclesonide nasal aerosol) for treatment of allergic rhinitis to Covis N.L. Alvesco, Omnaris and Zetonna were licensed from Takeda GmbH by Sunovion (formerly Sepracor) in 2008.

Respiratory Care
Respiratory Care
Learning Zone Homepage

Respiratory Care

The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.

Read more
530 mins
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Latest drug news
Drug news
CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Triumeq.

1 mins
Drug news
CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min
Drug news
CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Alecensa.

1 min
See all news